May 4, 2021
As a growing healthcare market, India is of strategic importance to Bio Products Laboratory (BPL), the specialist manufacturer of plasma-derived medicinal products based in Elstree, UK, as the company continues to grow its global commercial presence there, and represents a business opportunity of up to £70M in the next 5 years.
BPL has been producing medicines for India for over 20 years to help patients in areas of critical care, haemophilia and coagulation disorders, providing its plasma-derived therapies to several key partners in India.
BPL’s high-quality plasma products are available in more than 30 countries around the world and the company has made significant investments in recent years to grow the reach of its Therapeutics business, increasing production at its UK manufacturing site and further strengthening its commercial presence worldwide, with sales in 2020 growing by +22%.
UK Prime Minister Boris Johnson said, “I’m delighted that Bio Products Laboratory is growing its presence in India to make the most of the opportunities for UK businesses in one of the world’s biggest economies. Our exporters are brilliant ambassadors for Britain and I hope today’s announcement is just the start of what you can do for India and the UK.”
Bob Rossilli, Chief Commercial Officer, Global Business, BPL Therapeutics, commented: “We are delighted to see the UK’s positive engagement with India, and as we look to build our global commercial relationships, India continues to be an important market.”
About Bio Products Laboratory (BPL)
Recognising the power of plasma and with many years of experience in the industry, BPL supplies high-quality plasma derived medicines to meet the needs of clinicians, patients and customers globally. Headquartered in the United Kingdom and with plasma collection centres across the United States, we are dedicated to producing medicines for the treatment of immune deficiencies, bleeding disorders and infectious diseases as well for critical care. BPL invests in the latest R&D, technology and manufacturing methods, and continuously adapts to ensure that we continue to serve all our stakeholders effectively. For more information visit http://www.bplgroup.com or https://www.bpl-us.com/.
BPL consists of two operating divisions — BPL Plasma and BPL Therapeutics. BPL Plasma, headquartered in Austin, Texas and operating in the USA, collects plasma from donors, in around 26 centres across the US. BPL Plasma employs over 900 staff, to support the needs of donors and to ensure high-quality plasma collection in all their centres. Plasma collection is regulated by both FDA and MHRA, and BPL Plasma follow industry guidelines. BPL Plasma operates clean and safe plasma facilities, staffed with trained personnel, dedicated to supporting donors through the process that leads to the donation of plasma. Plasma is shipped to the headquarters of BPL Therapeutics in Elstree, United Kingdom. The plasma is fractionated, purified, and filled through the efforts of our over 1,000 employees involved in production, quality, R&D, commercial, customer services and administrative activities. BPL’s plasma derived medicines are commercially available in the UK, USA and 30 plus other countries around the world through our network of local affiliates and distribution partners.
For more information on Product: